Funding will accelerate science led longevity solutions, microbiome platform and research driven supplements for healthy ageing
Decode Age, a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science, has raised Rs 14.48 crore in its Pre Series A funding round led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India.
The investment aims to strengthen the company’s mission to make the biology of ageing measurable, understandable and actionable through science led solutions and a microbiome centred longevity ecosystem.
Decode Age has built a longevity research platform that spans multi omics testing, biomarker discovery and precision-based interventions along with advanced whole genome gut microbiome analysis systems, providing insights into microbial diversity and its influence on immunity, metabolism and ageing pathways.
The company is using these insights to develop a new generation of research driven supplements and longevity solutions that are informed by ageing biology and microbiome data. The focus is on supporting healthy ageing and biological pathways that sit behind age related conditions such as cancer, dementia and other chronic diseases, in line with prevailing scientific evidence and regulatory standards. The new capital will enable Decode Age to expand biomarker discovery programmes, advance its multi omics and microbiome research pipeline and enhance scientific and analytical infrastructure. It will also support formulation research aligned with key hallmarks of ageing, including areas such as cellular energy, metabolic balance, inflammatory pathways and cognitive resilience, as well as deeper collaboration across the longevity ecosystem.
Speaking about the investment, Parth Amin, CEO and Co-founder, Decode Age, said, “This investment marks an important step forward in our mission to bring scientific precision to the way people understand their biology. The support from Dr Chigurupati strengthens our ability to advance ageing and gut microbiome research, expand our biomarker programmes and build the scientific infrastructure that drives our work. We are grateful for his belief in our vision and remain committed to translating rigorous science into insights that help individuals make informed decisions about their long-term health.”
Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India added, “Decode Age is advancing an area of science that will redefine how we think about health, disease and ageing. Their capabilities in gut microbiome research and ageing biology are rigorous and forward-looking, offering individuals and clinicians biological insights that were previously inaccessible. This investment reflects my confidence in their scientific vision and the long-term impact they aim to create.”
